Michil Androsov and Igor Gurovich have a simple pitch: What if combating social isolation among the elderly didn't require convincing 80-year-olds to download an app or strap on a smartwatch?
Their San Francisco startup, Callie Care, offers something decidedly low-tech in execution, if not in ambition—a phone-based AI assistant that calls seniors daily to check in, remind them about medications, and monitor their wellbeing. No smartphone required. No hub to plug in. Just a regular phone call, whether it's ringing a landline or lighting up a flip phone.
The company has raised $500,000 in pre-seed funding, according to a StartupHub.ai directory listing, though details about investors and exact timing remain undisclosed. Founded in 2025, Callie Care is threading a needle between two enormous populations: the roughly 16.2 million older Americans living alone (per 2023 estimates from the MSD Manual Professional) and the 53 million unpaid family caregivers scrambling to support them from afar, as of 2020 according to a NAC/AARP survey cited by the CDC.
Whether those two groups will embrace a synthetic voice as a stand-in for human connection is, perhaps, the central question.
More Than Just a Friendly Call
Callie Care's service goes beyond pleasantries. The AI handles daily wellness check-ins, sure, but it also coordinates logistics that often overwhelm caregivers: scheduling doctor's appointments, booking rides, ordering groceries. It will nag about medications. And crucially, it listens—analyzing vocal patterns for subtle shifts that might signal cognitive decline, emotional distress, or physical deterioration.
The company frames this as "vocal biomarker" analysis, a term that sounds almost medical in its precision. There's some science backing the concept. A November 2024 study from the National Institute on Aging found that AI parsing speech transcripts could predict the progression from mild cognitive impairment to Alzheimer's with over 78% accuracy, though the research remains early-stage. Still, translating research findings into a reliable consumer product is where many health tech ventures stumble.
The startup launched its MVP in mid-October 2025. By mid-2026, company-reported metrics indicated more than 8,000 users had tried the service, according to a TechRound profile, with 85% of engaged users opting to continue receiving calls. The company's own check-in page claims over 10,000 calls completed, though there's a discrepancy between a reported 4.8 average rating on some materials and a 5-star rating on the homepage—solid, if modest, early traction for a young company.
One curious wrinkle: pricing. The main site advertises a $15 monthly subscription with a three-day trial, while a separate page lists $39.99 per month with a seven-day trial. The discrepancy suggests Callie Care is experimenting with different tiers or testing what the market will bear. Neither founders nor the company have clarified the disconnect publicly.
A Crowded Field, But Room to Maneuver
Callie Care isn't alone in betting on AI companionship for seniors. The field has attracted serious capital and serious players. Intuition Robotics, maker of the ElliQ tabletop robot, pulled in $25 million in August 2023 and has been deployed in state-sponsored programs. Care.coach, which pairs avatar-based companionship with human supervisors, has raised north of $10 million and secured NIH funding. Then there are phone-first competitors like DailyCall, Ruth Daily, and AvenoraCall—each taking their own angle on the same fundamental insight: older adults are lonely, and technology might help, if only it weren't so damn complicated.
Where Callie Care differentiates itself is accessibility. No hardware to ship. No learning curve steeper than answering the phone. That could be a meaningful advantage in a demographic not known for its enthusiasm toward gadgets.
The team itself remains lean—company LinkedIn suggests a size of 2-10 employees—but has brought on advisors with relevant expertise. Julie Brown, a gerontologist specializing in age tech, and Israel Cross, a public health gerontologist, both lend credibility. (Both were quoted in an NBC Select feature on senior technology in May 2026, suggesting they're active voices in the space.)
What Comes Next
The $500,000 pre-seed gives Callie Care runway, though not much—enough to refine the product, expand the user base, and hopefully secure a proper seed round. The company hasn't disclosed specific plans for the capital, but its roadmap emphasizes two priorities: deepening its vocal biomarker capabilities and forging partnerships with home care agencies and health insurers.
That second goal may be the harder lift. Insurers move slowly, and proving clinical outcomes—not just user satisfaction—will be essential for any partnership that involves reimbursement. For now, Callie Care remains a direct-to-consumer play, dependent on families willing to pay out of pocket for peace of mind.
Whether that peace of mind comes from an AI or a human voice may, in the end, matter less than whether someone—anyone—is calling at all.
